Dr. Joseph Mikhael Joins the International Myeloma Foundation as Chief Medical Officer

"Dr. Mikhael has a tremendous passion for education and travels the world lecturing and developing collaborations in the myeloma community," said Susie Durie, the IMF's President, Founder, and CEO. "He is the ideal fit to be our Chief Medical Officer, and we are excited to have him join the team."

Having been a professor of medicine at Mayo Clinic and a world-renowned expert in myeloma, Dr. Mikhael brings a wealth of this experience to this new role. He has conducted dozens of clinical trials in the field of myeloma and has contributed to the development of many novel drugs. He also served as the Associate Dean of Graduate Medical Education and the Deputy Director of the Mayo Clinic Comprehensive Cancer Center.

"Dr. Joseph Mikhael brings extensive experience in myeloma treatment and research to his new position with the IMF," said IMF Chairman Dr. Brian Durie. "In addition, his experience on the global stage makes him perfectly suited to playing an important role in our growing research efforts around the world."

Dr. Mikhael also serves as a councilor on the American Society of Hematology (ASH) Executive and is involved in mentoring the next generation of hematologists. He did his medical training in Canada, having completed medical school at the University of Ottawa, his hematology training at the University of Toronto and a Multiple Myeloma Fellowship at Princess Margaret Hospital. He also has a Master's degree in Education from the University of Toronto.

In addition, Dr. Mikhael will remain in clinical and academic medicine with City of Hope Cancer Center.

ABOUT THE INTERNATIONAL MYELOMA FOUNDATION
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest foundation focusing specifically on multiple myeloma. The Foundation's reach extends to more than 450,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure by focusing on four key areas: research, education, support, and advocacy. The IMF has conducted more than 250 educational seminars worldwide, maintains a world-renowned InfoLine, and in 2001, established the International Myeloma Working Group (IMWG), a collaborative research initiative focused on improving myeloma treatment options for patients. In 2012, the IMF launched the Black Swan Research Initiative^®, a groundbreaking research project aimed at curing myeloma. The IMF can be reached at (800) 452-CURE (2873). The global website is www.myeloma.org. Follow the IMF on Twitter @IMFmyeloma.

CONTACT:

Sapna Kumar [email protected] (818) 487-7455

SOURCE International Myeloma Foundation

Related Links

http://www.myeloma.org